Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases
- PMID: 31470176
- PMCID: PMC7044053
- DOI: 10.1016/j.cgh.2019.08.042
Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases
Abstract
Background & aims: We investigated 30- and 90-day rates and causes of, risk factors for, and interventions to reduce hospital readmission in patients who received medical treatment for inflammatory bowel diseases (IBD).
Methods: We performed a systematic search of publications through July 1, 2018 for studies of rates of hospital readmission and associated causes and risk factors in patients who received medical treatments for IBD. Our final analysis included 17 cohort studies (6324 patients) of hospitalized adults with IBD who had received medical treatment, along with reported readmission rates with detailed chart review. We performed random effects meta-analysis to estimate 30- and 90-day rates of readmission and identified causes and risk factors associated with readmission. We also performed qualitative analyses of studies that focused on interventions to reduce readmission.
Results: Overall, the 30-day rate of readmission was 18.1% (95% CI, 14.4-22.4) and the 90-day rate was 26.0% (95% CI, 22.7-29.6). On meta-regression, studies with higher proportions of patients with ulcerative colitis than Crohn's disease reported higher risks for readmission. Most common reasons for readmission were IBD flare, infection, or complications from unplanned surgeries during hospitalizations. Consistent risk factors for 30-day readmission were admission for pain control (odds ratio [OR], 2.27; 95% CI, 1.69-3.03), need for total parenteral nutrition on discharge (OR, 2.13; 95% CI, 1.36-3.35), and prior or unplanned surgery during admission (OR, 3.11; 95% CI, 2.27-4.25). Only 1 study focused on interventions (specialized inpatient IBD service) to reduce risk of readmission.
Conclusions: Overall 30- and 90-day rates of readmission for patients who received medical treatment for IBD are 18.1% and 26.0%, respectively. IBD flares and infections are common reasons for readmission, and inadequate pain control and need for parenteral nutrition were common risk factors. Interventional studies to reduce risk of readmission are needed.
Keywords: Burden; CD; Population Health; UC; Value-Based Care.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Inflammatory Bowel Disease: Predictors and Causes of Early and Late Hospital Readmissions.Inflamm Bowel Dis. 2017 Oct;23(10):1832-1839. doi: 10.1097/MIB.0000000000001242. Inflamm Bowel Dis. 2017. PMID: 28858068
-
Nonattendance to gastroenterologist follow-up after discharge is associated with a thirty-days re-admission in patients with inflammatory bowel disease: a multicenter study.Minerva Med. 2021 Aug;112(4):467-473. doi: 10.23736/S0026-4806.21.07442-5. Epub 2021 Apr 21. Minerva Med. 2021. PMID: 33881281
-
90-Day Specific Readmission for Clostridium difficile Infection After Hospitalization With an Inflammatory Bowel Disease Flare: Outcomes and Risk Factors.Inflamm Bowel Dis. 2021 Mar 15;27(4):530-537. doi: 10.1093/ibd/izaa224. Inflamm Bowel Dis. 2021. PMID: 32812037
-
The Relationship Between Opioid Use and Healthcare Utilization in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Inflamm Bowel Dis. 2022 Dec 1;28(12):1904-1914. doi: 10.1093/ibd/izac021. Inflamm Bowel Dis. 2022. PMID: 35230420 Free PMC article.
-
Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses.Gastroenterology. 2019 Sep;157(3):647-659.e4. doi: 10.1053/j.gastro.2019.04.016. Epub 2019 Apr 20. Gastroenterology. 2019. PMID: 31014995
Cited by
-
The Interaction between Stress and Inflammatory Bowel Disease in Pediatric and Adult Patients.J Clin Med. 2024 Feb 27;13(5):1361. doi: 10.3390/jcm13051361. J Clin Med. 2024. PMID: 38592680 Free PMC article. Review.
-
Impact of Comorbid Psychiatric Disorders on Healthcare Utilization in Patients with Inflammatory Bowel Disease: A Nationally Representative Cohort Study.Dig Dis Sci. 2022 Sep;67(9):4373-4381. doi: 10.1007/s10620-022-07505-9. Epub 2022 May 3. Dig Dis Sci. 2022. PMID: 35503486
-
Immunomodulatory potential of mesenchymal stem cell-derived extracellular vesicles: Targeting immune cells.Front Immunol. 2023 Feb 13;14:1094685. doi: 10.3389/fimmu.2023.1094685. eCollection 2023. Front Immunol. 2023. PMID: 36860847 Free PMC article. Review.
-
Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases.Clin Gastroenterol Hepatol. 2021 Jul;19(7):1377-1386.e5. doi: 10.1016/j.cgh.2020.05.056. Epub 2020 Jun 9. Clin Gastroenterol Hepatol. 2021. PMID: 32526341 Free PMC article.
-
National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States.Inflamm Bowel Dis. 2021 Jun 15;27(7):1068-1078. doi: 10.1093/ibd/izaa266. Inflamm Bowel Dis. 2021. PMID: 33051681 Free PMC article.
References
-
- Mehta F Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care 2016;22:s51–60. - PubMed
-
- Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54 e42; quiz e30. - PubMed
-
- Singh S, Brill JV, Proudfoot JA, et al. Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2018;16:1847–50 e1. - PubMed
-
- Dulai PS, Singh S, Ohno-Machado L, Sandborn WJ. Population Health Management for Inflammatory Bowel Disease. Gastroenterology 2018;154:37–45. - PubMed